Comparative Pharmacology
Head-to-head clinical analysis: IVERMECTIN versus STROMECTOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IVERMECTIN versus STROMECTOL.
IVERMECTIN vs STROMECTOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ivermectin is a macrocyclic lactone that binds selectively and with high affinity to glutamate-gated chloride ion channels in invertebrate nerve and muscle cells, leading to increased chloride ion influx, hyperpolarization, and paralysis of the parasite. It also interacts with other ligand-gated chloride channels, such as those gated by gamma-aminobutyric acid (GABA). In mammals, these channels are largely confined to the central nervous system, but ivermectin does not readily cross the blood-brain barrier, providing a safety margin.
Ivermectin acts by binding selectively and with high affinity to glutamate-gated chloride ion channels in invertebrate nerve and muscle cells, leading to increased permeability to chloride ions, hyperpolarization of nerve or muscle cells, and death of the parasite. It also interacts with other ligand-gated chloride channels, such as those gated by gamma-aminobutyric acid (GABA).
150–200 mcg/kg orally once, with repeat dose in 2 weeks for strongyloidiasis; for scabies, 200 mcg/kg orally once, repeat in 2 weeks if needed.
Oral: 200 mcg/kg once daily for 1-2 days. For strongyloidiasis, 200 mcg/kg/day for 2 days. For onchocerciasis, single dose of 150 mcg/kg.
None Documented
Clinical Note
moderateIvermectin + Teriflunomide
"The serum concentration of Teriflunomide can be increased when it is combined with Ivermectin."
Clinical Note
moderateIvermectin + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Ivermectin."
Clinical Note
moderateIvermectin + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Ivermectin."
Clinical Note
moderateIvermectin + Cyclosporine
None Documented
Terminal elimination half-life is approximately 18 hours (range 12-24 hours) in healthy adults; prolonged in hepatic impairment.
Terminal elimination half-life is approximately 18 hours (range 10–30 hours) in healthy subjects; prolonged in hepatic impairment.
Primarily fecal (≥90% as unchanged drug and metabolites); renal excretion is minimal (<1% of dose). Biliary excretion contributes to fecal elimination.
Primarily fecal (90%) as unchanged drug and metabolites; renal excretion accounts for <1% of the dose.
Category A/B
Category C
Anthelmintic
Anthelmintic
"The metabolism of Cyclosporine can be decreased when combined with Ivermectin."